Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Idelalisib + Rituximab in untreated CLL with 17p deletion
NCT02044822Phase 2Terminated
- Sponsor
- Gilead Sciences
- Start
- Aug 2014
- Primary completion
- Apr 2016
- Modality
- Small Molecules
- Countries
- 14
01
Overview
Phase 2, open-label, single-arm trial of idelalisib in chronic lymphocytic leukemia (CLL), sponsored by Gilead Sciences. Primary endpoint: Overall Response Rate. Started Aug 2014; status: terminated.
02
Drugs
idelalisib
03
Conditions
chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT02044822.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02044822.